Law360, New York (May 15, 2015, 10:20 AM EDT) -- Since completion of the Human Genome Project, genomic profiling and the related advent of personalized medicine have become a hot topic. Many predicted this new genomic information would lead to targeted drug treatments that work better with less risk. Along with this optimism came concern about new litigation, as plaintiffs seek and find novel liability theories. What have we seen? Translating scientific knowledge into clinical practice has presented difficulties, some expected and some surprising, but there have been exciting advances, too. Increasing computer power and data collection may drive major new breakthroughs. And while plaintiffs have found ways to use genomic data in products liability cases, defendants also have found ways to parry the novel allegations and riposte, with causation defenses supported by genomic evidence....